$11.5
+0.3
(+2.68%)▲
Revenue is up for the last 2 quarters, 24.0K → 1.12M (in $), with an average increase of 97.9% per quarter
Netprofit is down for the last 2 quarters, -15.15M → -17.82M (in $), with an average decrease of 17.6% per quarter
4.09%
Downside
Day's Volatility :4.5%
Upside
0.43%
96.7%
Downside
52 Weeks Volatility :97.75%
Upside
31.79%
Period | Ambrx Biopharma Inc-adr | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -30.13% | -3.0% | 0.0% |
6 Months | 28.35% | 0.5% | 0.0% |
1 Year | 964.81% | 6.3% | 6.3% |
3 Years | -46.06% | 22.1% | 17.3% |
Market Capitalization | 877.4M |
Book Value | $4.06 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -1.27 |
Wall Street Target Price | 23.67 |
Profit Margin | 0.0% |
Operating Margin TTM | -940.86% |
Return On Assets TTM | -14.39% |
Return On Equity TTM | -30.41% |
Revenue TTM | 5.6M |
Revenue Per Share TTM | 0.13 |
Quarterly Revenue Growth YOY | -13.5% |
Gross Profit TTM | 7.4M |
EBITDA | -52.1M |
Diluted Eps TTM | -1.27 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.51 |
EPS Estimate Next Year | -0.5 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 105.83%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 10.3M | - |
Net Income | -20.1M | - |
Net Profit Margin | -194.57% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 13.7M | ↑ 32.59% |
Net Income | -16.5M | ↓ 17.54% |
Net Profit Margin | -121.01% | ↑ 73.56% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 7.5M | ↓ 45.47% |
Net Income | -68.1M | ↑ 311.53% |
Net Profit Margin | -913.2% | ↓ 792.19% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 7.4M | ↓ 0.71% |
Net Income | -78.0M | ↑ 14.57% |
Net Profit Margin | -1.1K% | ↓ 140.52% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 2.2M | - |
Net Income | -13.3M | - |
Net Profit Margin | -590.36% | - |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 7.4M | ↑ 229.71% |
Net Income | -78.0M | ↑ 488.49% |
Net Profit Margin | -1.1K% | ↓ 463.36% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 24.0K | ↓ 99.68% |
Net Income | -15.2M | ↓ 80.57% |
Net Profit Margin | -63.2K% | ↓ 62096.28% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.1M | ↑ 4579.17% |
Net Income | -17.8M | ↑ 17.62% |
Net Profit Margin | -1.6K% | ↑ 61562.64% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 61.7M | - |
Total Liabilities | 28.3M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 134.0M | ↑ 117.12% |
Total Liabilities | 273.5M | ↑ 866.17% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 229.0M | ↑ 70.88% |
Total Liabilities | 39.1M | ↓ 85.72% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 147.0M | ↓ 35.82% |
Total Liabilities | 29.1M | ↓ 25.41% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 180.9M | - |
Total Liabilities | 39.0M | - |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 147.0M | - |
Total Liabilities | 29.1M | - |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 210.6M | ↑ 43.3% |
Total Liabilities | 28.0M | ↓ 3.8% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 279.9M | ↑ 32.92% |
Total Liabilities | 29.6M | ↑ 5.51% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -2.8M | - |
Investing Cash Flow | -48.0K | - |
Financing Cash Flow | 95.7M | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -20.6M | ↑ 644.16% |
Investing Cash Flow | -252.0K | ↑ 425.0% |
Financing Cash Flow | 95.7M | ↑ 0.0% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -44.6M | ↑ 116.95% |
Investing Cash Flow | -3.2M | ↑ 1172.22% |
Financing Cash Flow | 127.4M | ↑ 33.18% |
Q3 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -13.7M | ↑ 59.63% |
Investing Cash Flow | -809.5K | ↑ 2.02% |
Financing Cash Flow | 16.0M | ↓ 66.55% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -13.7M | ↑ 0.0% |
Investing Cash Flow | -809.5K | ↑ 0.0% |
Financing Cash Flow | 16.0M | ↑ 0.0% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -20.1M | ↑ 46.45% |
Investing Cash Flow | -32.1M | ↑ 3865.66% |
Financing Cash Flow | -17.0K | ↓ 100.11% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -20.1M | ↑ 0.0% |
Investing Cash Flow | -32.1M | ↑ 0.0% |
Financing Cash Flow | -17.0K | ↑ 0.0% |
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Ambrx Biopharma Inc-adr | -18.79% | 28.35% | 964.81% | -46.06% | -46.06% |
![]() Moderna, Inc. | -11.43% | -29.94% | -12.65% | 45.99% | 455.32% |
![]() Regeneron Pharmaceuticals, Inc. | -1.44% | 1.41% | 19.47% | 47.01% | 108.75% |
![]() Novo Nordisk A/s | -3.29% | 15.05% | 82.56% | 161.96% | 290.64% |
![]() Seagen, Inc. | 2.56% | 4.47% | 55.05% | 8.41% | 161.4% |
![]() Vertex Pharmaceuticals Incorporated | -0.86% | 11.4% | 20.1% | 27.79% | 81.52% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Ambrx Biopharma Inc-adr | 1.36 | NA | NA | -0.51 | -0.3 | -0.14 | 0.0 | 4.06 |
![]() Moderna, Inc. | 34.94 | 34.94 | 0.0 | -3.66 | 0.07 | 0.01 | 0.0 | 44.49 |
![]() Regeneron Pharmaceuticals, Inc. | 22.08 | 22.08 | 9.01 | 41.82 | 0.19 | 0.1 | 0.0 | 225.94 |
![]() Novo Nordisk A/s | 43.05 | 43.05 | 2.03 | 1.64 | 0.82 | 0.22 | 0.01 | 2.52 |
![]() Seagen, Inc. | NA | NA | 18.53 | -3.52 | -0.26 | -0.13 | 0.0 | 13.96 |
![]() Vertex Pharmaceuticals Incorporated | 26.67 | 26.67 | 0.41 | 14.71 | 0.25 | 0.16 | 0.0 | 60.01 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Ambrx Biopharma Inc-adr | Buy | $877.4M | -46.06% | 1.36 | 0.0% |
![]() Moderna, Inc. | Buy | $38.2B | 455.32% | 34.94 | 11.33% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $90.6B | 108.75% | 22.08 | 33.93% |
![]() Novo Nordisk A/s | Buy | $412.6B | 290.64% | 43.05 | 33.4% |
![]() Seagen, Inc. | Hold | $39.8B | 161.4% | NA | -33.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $89.7B | 81.52% | 26.67 | 35.4% |
Darwin Global Management, Ltd.
Cormorant Asset Management, LLC
D. E. Shaw & Co LP
COMMODORE CAPITAL LP
VR Adviser, LLC
Farallon Capital Management, L.L.C.
ambrx, inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics. ambrx is based on a fundamental advance in protein biosynthesis that enables the company to genetically engineer proteins with new amino acid building blocks beyond the common twenty, enabling the biosynthesis of proteins with new physical, chemical and pharmacological properties. at ambrx, we are dedicated to assembling and developing an exceptional team and a breakthrough technology to create the next generation of protein-based medicines.
Organization | Ambrx Biopharma Inc-adr |
Employees | 79 |
CEO | Ms. Sonja Nelson CPA |
Industry | Healthcare |
Dynavax Technologies Corporation
$11.50
+2.68%
Lemaitre Vascular Inc
$11.50
+2.68%
Collegium Pharmaceutical Inc
$11.50
+2.68%
Agios Pharmaceuticals, Inc.
$11.50
+2.68%
Eagle Pharmaceuticals Inc.
$11.50
+2.68%
Scilex Holding Co
$11.50
+2.68%
Bluebird Bio, Inc.
$11.50
+2.68%
Acorda Therapeutics, Inc.
$11.50
+2.68%
Mannkind Corp.
$11.50
+2.68%